NANO.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	49 210.00
Średni wolumen	44 250.00
Kapitalizacja rynkowa	261.94M
EPS	€0 ( 2024-04-24 )
Następna data zysków	( €0 ) 2024-05-15
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-3.31
ATR14	€0.0100 (0.18%)

Wolumen Korelacja

Długi: -0.06 (neutral)

Krótki: 0.25 (neutral)

Signal:(48.901) Neutral

Nanobiotix SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nanobiotix SA Korelacja - Waluta/Towar

-0.35
( neutral )

-0.49
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.49
( neutral )

-0.11
( neutral )

Nanobiotix SA Finanse

Annual	2022
Przychody:	€4.78M
Zysk brutto:	€3.28M (68.59 %)
EPS:	€-1.640

FY	2022
Przychody:	€4.78M
Zysk brutto:	€3.28M (68.59 %)
EPS:	€-1.640

FY	2021
Przychody:	€10 000.00
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-0.448

FY	2020
Przychody:	€50 000.00
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-1.380

Financial Reports:

No articles found.

Nanobiotix SA

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.